Incident diverticulitis, perforations and lethal perforations
| Total no. of diverticulitis | ||||
|---|---|---|---|---|
| PYs | (Incidence rate/1000 PYs (95% CI)) | Thereof: no. of LIP (proportion, (95% CI*)) | No. of patients died within 30 days after LIP (proportion, (95% CI*)) | |
| csDMARDs | 18 113 | 34 (1.9 (1.3 to 2.6)) | 11 (32.4 (17.4 to 50.5)) | 1 (9.1 (0.0 to 41.3)) |
| TNFi | 24 851 | 37 (1.5 (1.1 to 2.1)) | 13 (35.1 (20.2 to 52.5)) | 3 (23.1 (5.0 to 53.8)) |
| Tocilizumab | 4082 | 16 (3.9 (2.2 to 6.4)) | 11 (68.7 (41.3 to 89.0)) | 5 (45.5 (16.8 to 76.6)) |
| Abatacept | 1976 | 1 (0.5 (0.0 to 2.8)) | 1 (100 (2.5 to 100)) | 0 (0 (0 to 97.5)) |
| Rituximab | 4950 | 4 (0.8 (0.2 to 2.1)) | 1 (25.0 (0 to 80.6)) | 0 (0 (0 to 97.5)) |
| Total | 53 972 | 92 (1.7 (1.4 to 2.1)) | 37 (40.2 (30.1 to 31.0)) | 9 (24.3 (11.8 to 41.2)) |
*Exact Clopper-Pearson 95% CI for the proportion.
csDMARDs, conventional synthetic disease-modifying anti-rheumatic drugs; IR, incidence rate per 1000 PYs; LIP, lower intestinal perforations; PYs, patient years; TNFi, tumour necrosis factor-α inhibitor.